Browse the evidence

Each 5-unit increment in BMI was associated with a 20% increased risk of early-onset CRC (RR 1.20).

Weight management strategies may be important for reducing early-onset CRC risk.

From 1999 to 2018, the estimated percentage of total energy from consumption of ultraprocessed foods increased from 61.4% to 67.0%.

Practitioners should be aware of the increasing trend in ultraprocessed food consumption among youths.

The percentage of total energy from consumption of unprocessed or minimally processed foods decreased from 28.8% to 23.5% from 1999 to 2018.

Practitioners should note the decline in consumption of unprocessed foods among youths.

There was a significantly larger increase in the estimated percentage of energy from ultraprocessed foods among non-Hispanic Black youths and Mexican American youths compared to non-Hispanic White youths.

Practitioners should consider demographic factors when addressing dietary habits among youths.

About 14% caloric restriction for 2 years in healthy humans improved thymopoiesis.

Caloric restriction may enhance immune function in healthy individuals.

Caloric restriction-induced transcriptional reprogramming in adipose tissue implicated pathways regulating mitochondrial bioenergetics, anti-inflammatory responses, and longevity.

Caloric restriction may promote metabolic health through specific molecular pathways.

Reduction of PLA2G7 may mediate the immunometabolic effects of caloric restriction and could potentially lower inflammation and extend health span.

Targeting PLA2G7 may be a strategy to reduce inflammation and improve health span.

Use of GLP-1 receptor agonists (GLP-1 RAs) is associated with an increased risk of gallbladder or biliary diseases (RR, 1.37; 95% CI, 1.23-1.52).

Healthcare providers should be aware of the potential increased risk of gallbladder diseases when prescribing GLP-1 RAs.

GLP-1 RA use is associated with a higher risk of gallbladder or biliary diseases at higher doses (RR, 1.56; 95% CI, 1.36-1.78) compared to lower doses (RR, 0.99; 95% CI, 0.73-1.33).

Dosing strategies for GLP-1 RAs should consider the potential increased risk of gallbladder diseases.

GLP-1 RA use remained low overall for treatment of T2D, particularly among patients with ASCVD.

Clinicians should recognize the need for increased GLP-1 RA prescribing, especially for patients with ASCVD.

Obesity is a major contributor to primary hypertension through mechanisms such as neurohormonal activation, inflammation, and kidney dysfunction.

Addressing obesity is crucial for managing hypertension risk.

Lifestyle modifications have limited long-term success in reducing adiposity and blood pressure in patients with obesity.

Practitioners should consider alternative strategies beyond lifestyle modifications for effective obesity management.

One-year discontinuation was significantly higher for patients without type 2 diabetes (64.8%) compared with those with type 2 diabetes (46.5%).

Practitioners should be aware that patients without type 2 diabetes may struggle more with adherence to GLP-1 RA therapy.

The association between glycemic load and cardiovascular events was similar to that of glycemic index among participants with cardiovascular disease at baseline, but not significant among those without preexisting cardiovascular disease.

Glycemic load may be a relevant factor for cardiovascular risk in individuals with existing conditions, but less so for those without.

There is a need for more accurate measures of muscle mass and function for diagnosing sarcopenia.

Practitioners should seek to utilize more accurate measurement tools for assessing sarcopenia.

There is a significant and growing public interest in Ozempic and related GLP-1 agonists.

Healthcare providers should be prepared for increased inquiries about these medications.

Bariatric surgery was associated with a lower incidence of cardiovascular mortality, with an adjusted hazard ratio of 0.35.

Bariatric surgery may lead to lower rates of death from cardiovascular causes in this population.

Bariatric surgery was associated with a lower incidence of the secondary outcome of 3-component MACE, with an adjusted hazard ratio of 0.66.

Bariatric surgery may reduce the risk of combined cardiovascular events in this patient group.

Ozempic users increased from 569 in 2019 to 7667 in 2020, with a count of 22,891 in 2022.

Practitioners should be aware of the rapid increase in Ozempic usage, indicating its growing acceptance and demand.

Intakes of saturated fatty acids (SFAs), trans-fatty acids, animal monounsaturated fatty acids (MUFAs), α-linolenic acid, and arachidonic acid were associated with higher mortality.

Reducing intake of these fats may lower mortality risk.

Global mean intake of processed meat was 17 g/day, with mean national intakes of at least one serving per day for processed meat in countries representing 6.9% of the global population.

Health professionals should consider the prevalence of processed meat consumption in their dietary recommendations.

Adverse events were more frequent with liraglutide, with 80% of participants experiencing gastrointestinal events compared to 57% with placebo.

Clinicians should monitor for gastrointestinal side effects when prescribing liraglutide.

Resmetirom achieved resolution of steatohepatitis without worsening of fibrosis in 26%-30% of participants compared to 10% for placebo.

Resmetirom may be an effective treatment option for patients with MASH and moderate to advanced liver fibrosis.

Resmetirom improved fibrosis without worsening of steatohepatitis in 24%-26% of participants compared to 14% for placebo.

Resmetirom may help improve liver fibrosis in patients with MASH without worsening their condition.